In this regard, inhibition of Ornithine decarboxylase (ODC), the first and rate-limiting enzyme in the polyamine biosynthesis pathway, and a direct MYC transcriptional target11 has been proposed as a potential therapeutic option in malignancies driven by the MYC oncogenes, such as lymphoma and neuroblastoma10,12. The gene discussed is MYC; the disease is lymphoma.